Novo Nordisk: This Won't Last

Novo Nordisk (NVO) reported robust Q2 2025 results, with revenue up 22% year-over-year in constant currency to DKK 65.3 billion and operating profit rising 23%, largely driven by 67% growth in Wegovy and 35% in Ozempic sales. Despite this strong performance, including a near doubling of obesity care sales, the company slightly trimmed full-year guidance due to factors like production constraints and changing payer dynamics, contributing to a recent stock decline of nearly 15% from its highs. However, the article frames this as a buying opportunity, citing NVO's dominant GLP-1 market share, significant manufacturing expansion plans, and a robust pipeline aimed at meeting still-outpacing demand, while acknowledging ongoing competitive and political risks.

Analysis

Novo Nordisk (NVO) demonstrated robust fundamental performance in its Q2 2025 earnings report, with revenue growing 22% year-over-year in constant currency to DKK 65.3 billion and operating profit increasing 23% to DKK 31.5 billion. This growth is primarily fueled by its GLP-1 franchise, where Wegovy sales surged 67% and Ozempic sales rose 35%. The company's strategic focus on obesity care is yielding significant results, with the segment nearly doubling its sales year-over-year to account for 18% of total revenue. Despite this strength, the company faces headwinds, leading to a slight reduction in full-year sales growth guidance to 21-25% from a previous 22-26%. Key challenges cited include production constraints limiting sales, alongside higher-than-expected rebates and shifting payer dynamics. The analysis highlights that while GLP-1 growth rates are moderating, demand continues to significantly outpace supply. To address this, NVO is making substantial investments to double its fill-finish capacity by 2026. While the company maintains a dominant market share of over 65% in GLP-1s and a strong pipeline, including a tablet version of Wegovy slated for 2026, risks persist. These include a high forward Price/Cash Flow multiple, pricing pressure, and potential political scrutiny on pharmaceutical costs.

Key Decisions for Investors

• Given the strong underlying growth in Q2 and dominant market position, investors could interpret the recent stock decline of nearly 15% from its highs as a potential long-term buying opportunity, as argued in the report.
• It is critical to monitor the execution of Novo Nordisk's manufacturing expansion, as its ability to resolve supply constraints will directly impact its capacity to meet overwhelming demand and defend its market share against competitors like Eli Lilly.
• Investors should remain vigilant of identified headwinds, including pricing pressure from payer negotiations and potential political risks, which could impact margins and valuation, particularly given the stock's rich forward Price-to-Cash Flow multiple.
• Future catalysts to watch include milestones from the drug pipeline, especially the anticipated 2026 launch of an oral Wegovy tablet and clinical data for next-generation therapies like CagriSema, which could significantly expand the company's addressable market.